"PMA DAYS" FOR FDA/SPONSOR RESOLUTION OF OUTSTANDING ISSUES ARE ENCOURAGED
This article was originally published in The Gray Sheet
Executive Summary
"PMA DAYS" FOR FDA/SPONSOR RESOLUTION OF OUTSTANDING ISSUES ARE ENCOURAGED in an Office of Device Evaluation "Blue Book" memorandum on closure of premarket approval applications. As part of an effort to ensure efficient and timely review of PMAs, ODE divisions "should consider setting aside specific 'PMA days' during which reviewers and managers will work with PMA applicants to resolve issues necessary to bring closure to these PMAs," the memo says.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.